Hamzaoui A, Hamzaoui K
Hôpital Abderrahmen Mami, Ariana, et Faculté de Médecine, Tunis, Tunisie.
Rev Mal Respir. 2005 Dec;22(6 Pt 1):999-1019. doi: 10.1019/200530185.
Behçet's disease and Takayasu's arteritis are both forms of large vessel vasculitis involving autoreactive T cells active against HSP 60.
Behçet's disease is more common than Takayasu's arteritis. Pulmonary aneurysms represent the major complication of pulmonary Behçet's disease and have a poor prognosis, being associated with massive haemoptysis. In situ pulmonary artery thrombus can lead to pulmonary infarction. Superior vena cava thrombosis progresses slowly, allowing the development of a prominent collateral circulation. Vascular inflammation can spread to the mediastinum, the pleura and the lungs with diffuse pulmonary haemorrhages, bronchiolitis and organising pneumonia. Electron beam tomodensitometry and MRI are the best diagnostic techniques for assessing pulmonary vascular lesions. In Takayasu's arteritis the pulmonary arteries are less frequently involved than the aorta. Pulmonary hypertension (PHT) and lung infarcts can complicate pulmonary arterial involvement and the association of malaise, fever and weight loss with PHT is characteristic of the disease. The diagnosis is confirmed by imaging means, particularly MRI, demonstrating parietal vascular inflammation.
Treatment of both conditions is based upon steroids and immunosuppression. Endovascular treatment may be used in a complementary way for aneurysms, arterial occlusion, and vena cava obstruction. However, patients often respond poorly to treatment and clinical trials using TNFalpha blockade, interferon alpha and vasodilators are in progress.
白塞病和大动脉炎均为大血管血管炎的形式,涉及针对热休克蛋白60(HSP 60)的自身反应性T细胞。
白塞病比大动脉炎更常见。肺动脉瘤是肺白塞病的主要并发症,预后较差,与大量咯血相关。原位肺动脉血栓可导致肺梗死。上腔静脉血栓形成进展缓慢,可形成显著的侧支循环。血管炎症可蔓延至纵隔、胸膜和肺部,导致弥漫性肺出血、细支气管炎和机化性肺炎。电子束断层扫描和磁共振成像(MRI)是评估肺血管病变的最佳诊断技术。在大动脉炎中,肺动脉受累的频率低于主动脉。肺动脉高压(PHT)和肺梗死可使肺动脉受累复杂化,且PHT伴有不适、发热和体重减轻是该病的特征。通过影像学手段,尤其是MRI显示血管壁炎症来确诊。
这两种疾病的治疗均基于类固醇和免疫抑制。血管内治疗可作为动脉瘤、动脉闭塞和腔静脉阻塞的辅助治疗方法。然而,患者通常对治疗反应不佳,目前正在进行使用肿瘤坏死因子α(TNFα)阻滞剂、干扰素α和血管扩张剂的临床试验。